Style | Citing Format |
---|---|
MLA | Ashin ZF, et al.. "Synergistic Effect of Curcumin and Tamoxifen Loaded in Ph-Responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells." BMC Complementary Medicine and Therapies, vol. 24, no. 1, 2024, pp. -. |
APA | Ashin ZF, Sadeghimohammadi S, Vaezi Z, Najafi F, Adibamini S, Sadeghizadeh M, Naderimanesh H (2024). Synergistic Effect of Curcumin and Tamoxifen Loaded in Ph-Responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells. BMC Complementary Medicine and Therapies, 24(1), -. |
Chicago | Ashin ZF, Sadeghimohammadi S, Vaezi Z, Najafi F, Adibamini S, Sadeghizadeh M, Naderimanesh H. "Synergistic Effect of Curcumin and Tamoxifen Loaded in Ph-Responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells." BMC Complementary Medicine and Therapies 24, no. 1 (2024): -. |
Harvard | Ashin ZF et al. (2024) 'Synergistic Effect of Curcumin and Tamoxifen Loaded in Ph-Responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells', BMC Complementary Medicine and Therapies, 24(1), pp. -. |
Vancouver | Ashin ZF, Sadeghimohammadi S, Vaezi Z, Najafi F, Adibamini S, Sadeghizadeh M, et al.. Synergistic Effect of Curcumin and Tamoxifen Loaded in Ph-Responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells. BMC Complementary Medicine and Therapies. 2024;24(1):-. |
BibTex | @article{ author = {Ashin ZF and Sadeghimohammadi S and Vaezi Z and Najafi F and Adibamini S and Sadeghizadeh M and Naderimanesh H}, title = {Synergistic Effect of Curcumin and Tamoxifen Loaded in Ph-Responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells}, journal = {BMC Complementary Medicine and Therapies}, volume = {24}, number = {1}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Ashin ZF AU - Sadeghimohammadi S AU - Vaezi Z AU - Najafi F AU - Adibamini S AU - Sadeghizadeh M AU - Naderimanesh H TI - Synergistic Effect of Curcumin and Tamoxifen Loaded in Ph-Responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells JO - BMC Complementary Medicine and Therapies VL - 24 IS - 1 SP - EP - PY - 2024 ER - |